Full-Time

Senior Scientist 2

Computational Pathology, Precision Medicine Pathology

Posted on 8/21/2026

AbbVie

AbbVie

10,001+ employees

Global biopharmaceutical company developing medicines

Compensation Overview

$109.5k - $208.5k/yr

+ Long-term incentive program

South San Francisco, CA, USA

In Person

Master's, PhD

Category
Medical, Clinical & Veterinary (1)
Biology & Biotech (1)
Required Skills
MLOps
Microsoft Azure
Python
TensorFlow
Neural Networks
PyTorch
Machine Learning
AWS
Cell Biology
OpenCV
Computer Vision
Google Cloud Platform

Get referred to AbbVie

See people who can refer or advise you

Requirements
  • A Ph.D. in Computer Science, Electrical Engineering, Computational Biology, Bioinformatics, or a related field with an emphasis on computer vision or machine learning, or an M.S. with at least 5 years of relevant industry experience.
  • Experience with image analysis techniques, including segmentation, object detection, and classification, demonstrated through publications, open-source projects, or product development.
  • Proficiency in Python and experience using computer vision libraries such as OpenCV and machine learning frameworks such as TensorFlow and PyTorch.
  • Familiarity with MLOps practices, including deployment, monitoring, and lifecycle management of machine learning models in production environments.
  • Familiarity with cloud computing platforms and scalable artificial intelligence and machine learning pipelines, such as AWS, Azure, or Google Cloud Platform.
  • Ability to contribute to collaborative projects and explain technical concepts to interdisciplinary teams.
  • Strong problem-solving skills and demonstrated creative approaches to overcoming challenges.
Responsibilities
  • Develop, train, and validate machine learning models for tissue image analysis, including segmentation, object detection, and classification.
  • Apply deep learning and representation learning techniques to challenges in digital pathology.
  • Curate and maintain large-scale pathology datasets, ensuring data quality and integrity for model training and evaluation.
  • Develop and implement tools and pipelines for data preprocessing, feature engineering, and model deployment.
  • Collaborate with pathologists, biologists, statisticians, data analysts, and engineers to integrate machine learning solutions into existing workflows.
  • Assist in external collaborations with research partners to enhance project outcomes and foster innovation.
  • Evaluate histopathology and spatial omics datasets to identify biomarkers that inform patient stratification and companion diagnostic efforts.
  • Monitor developments in artificial intelligence, machine learning, and digital pathology techniques and apply relevant insights to ongoing projects.
Desired Qualifications
  • Exposure to digital pathology or biomedical imaging, including histopathology, microscopy, or tissue imaging datasets.
  • Experience with spatial omics data or integrating molecular data with image analysis.
  • Working knowledge of precision medicine, biomarker discovery, or personalized treatment strategies.
  • Familiarity with cell and molecular biology concepts in oncology, immunology, or cancer immunotherapy, or eagerness to learn.

AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.

Company Size

10,001+

Company Stage

IPO

Headquarters

North Chicago, Illinois

Founded

1888

Get referred to AbbVie

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • AbbVie raised 2026 revenue guidance to about $67.6 billion after Q2 beat.
  • SKYRIZI pediatric psoriasis approvals and Crohn's dosing decision this fall expand the franchise.
  • Tavapadon's FDA decision in Q3 2026 could create another Parkinson's launch next year.

What critics are saying

  • Humira revenue fell 36% in Q2 2026 from relentless biosimilar competition.
  • Epcoritamab missed its U.S. Phase 3 endpoint on July 23, 2026, weakening lymphoma ambitions.
  • Apogee's $10.9 billion deal cuts 2026 EPS, and heavy debt issuance raises leverage.

What makes AbbVie unique

  • SKYRIZI and RINVOQ drove Q2 2026 immunology revenue to $8.79 billion.
  • AbbVie paired scale with cash generation, converting roughly 28% of revenue into free cash flow.
  • Botox, Vraylar, and Vyalev diversify AbbVie beyond immunology into aesthetics and neuroscience.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

3%

1 year growth

3%

2 year growth

3%
Yahoo Finance
Aug 21st, 2026
AbbVie stock moves independently from market with 0.22 correlation driven by immunology drugs

AbbVie stock shows a correlation of just 0.22 to the S&P 500 over five years, meaning most of its movements stem from company-specific factors rather than broader market trends. The pharmaceutical firm's immunology segment generated nearly $8.8 billion of its $17 billion in second-quarter 2026 revenue, led by SKYRIZI at $5.5 billion and RINVOQ at over $2.5 billion. These treatments for chronic diseases have prices negotiated with payers, not consumers. AbbVie has delivered an annualised return of 21.5% with 23.5% volatility over five years, compared to the S&P 500's 12.9% return at 17.2% volatility. The company converts 28.3% of revenue into free cash flow, nearly double the S&P 500 median of 14.5%.

Yahoo Finance
Aug 19th, 2026
AbbVie stock eyes breakout as Skyrizi dosing decision could unlock $24.5B revenue growth

AbbVie stock has returned 24.5% over the past three months, trading near its 52-week high. The pharmaceutical company's growth hinges on a pending regulatory decision for SKYRIZI, an immunology treatment that generates nearly a third of guided revenue. SKYRIZI sold $5.5 billion in Q2 2026, up 24% operationally. AbbVie guides the drug to $21.7 billion for 2026 against total company revenue of approximately $67.6 billion. The company has raised its 2026 guidance twice by $600 million combined. A subcutaneous induction option for Crohn's disease awaits regulatory approval this fall. Management expects the new dosing method to meaningfully accelerate SKYRIZI sales, though the commercial impact won't materialise until early 2027 due to contract timelines. Clinical trial results showed endoscopic response and remission rates 25 points above placebo.

BBC
Aug 19th, 2026
UK's Smith+Nephew CFO John Rogers to step down for external role.

UK's Smith+Nephew CFO John Rogers to step down for external role. August 19, 2026 The departure follows Smith+Nephew's decision weeks ago to cut its annual revenue growth forecast after second-quarter sales missed expectations due to weak U.S. knee and hip implant demand and pressure on skin substitute pricing International News via Reuters: Smith+Nephew said on Wednesday its finance chief John Rogers would step down at the end of September to take up an external position in the United States, ending his roughly two-and-a-half-year tenure with the medical products company. Here are some more details: - The departure follows Smith+Nephew's decision weeks ago to cut its annual revenue growth forecast after second-quarter sales missed expectations due to weak U.S. knee and hip implant demand and pressure on skin substitute pricing. - Smith+Nephew said it had appointed Senior Vice President Finance and Group Controller Pierre Palassian as interim chief financial officer until a permanent replacement was appointed. - Palassian, who joined Smith+Nephew in 2017, previously held senior roles at AbbVie and Abbott Laboratories. - Rogers, who took up the CFO role in early 2024, had relocated to the United States in 2025 for operational efficiencies. - Shares in the FTSE 100 company have gained nearly 14% during Rogers' tenure as CFO. - Smith+Nephew said Rogers would receive no severance payment, and that his outstanding incentive and share awards would lapse on September 30 under leaver rules. Reporting by Neeshita Beura in Bengaluru; Editing by Subhranshu Sahu - Advertisement - August 19, 2026 - Advertisement -

Yahoo Finance
Aug 15th, 2026
AbbVie shows strong cash flow margin of 34.8% but faces tepid revenue growth

AbbVie, the biopharmaceutical company spun off from Abbott Laboratories in 2013, has risen 9.7% to $249.64 per share over the past six months. The company generates $64.39 billion in revenue over the past 12 months, benefiting from significant economies of scale in its operations. AbbVie's free cash flow margin averaged 34.8% over the last five years, amongst the best in the healthcare sector. This strong cash generation enables reinvestment and capital returns to investors. However, the company's five-year annualised revenue growth of 3.7% remains tepid compared to sector peers. Despite this weakness, AbbVie's shares trade at 16.3 times forward price-to-earnings ratio. The company develops and markets medications for autoimmune diseases, cancer, neurological disorders, and other complex health conditions.

Yahoo Finance
Aug 13th, 2026
Genmab raises 2026 revenue guidance to $4.5B despite epcoritamab setback; AbbVie reports $17B Q2 revenue

Genmab and AbbVie confirmed on 23 July that their jointly developed bispecific antibody epcoritamab failed to meet its primary endpoint in a Phase 3 trial. The study evaluated epcoritamab monotherapy against chemoimmunotherapy in transplant-ineligible adults with relapsed/refractory diffuse large B-cell lymphoma. In the US, where overall survival was the sole primary endpoint, the trial did not demonstrate statistically significant improvement. Despite the setback, epcoritamab maintains its accelerated FDA approval. Both companies will review the full data set with regulators to determine next steps. Genmab reported H1 2026 revenue of $2.051 billion, up 25% year-over-year, raising full-year guidance to $4.325–$4.525 billion. AbbVie posted Q2 2026 net revenues of $16.99 billion, up 10.2%, driven by its immunology portfolio generating $8.79 billion.